CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Proteo Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Proteo Inc
2102 Business Center Drive
Phone: (949) 253-4616p:949 253-4616 IRVINE, CA  92612  United States
This company is no longer actively traded on any major stock exchange.
Business Summary
Proteo, Inc. is a clinical-stage drug development company that is focused on the development of anti-inflammatory treatments for rare diseases. Its drug candidate Tiprelestat (also known as Elafin) is used for the treatment of acute postoperative inflammatory complications, in particular after esophageal cancer surgery. Elafin is also used for the treatment of pulmonary arterial hypertension, for preventing complications of organ transplantation and for treatment of acute respiratory distress syndrome (ARDS). The Company has obtained Orphan drug designations within the European Union for the use of Elafin for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension as well as for the treatment of esophageal cancer. Within the United States, it has obtained Orphan drug designations for the use of Elafin for the treatment of pulmonary arterial hypertension as well as for the prevention of inflammatory complications of transthoracic esophagectomy.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202012/31/2019YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Chief Financial Officer, Director OliverWiedow 61 11/15/2018 12/1/2000
Chief Operating Officer JuergenPaal 43 12/1/2014 12/1/2014
Director JorkVon Reden 75 11/15/2018 11/15/2018
Director HartmutWeigelt 69 12/1/2000 12/1/2000

Business Names
Business Name
PAHI
Proteo Biotech AG
PTEO
PTEOD

General Information
Number of Employees: 4 (As of 12/31/2013)
Outstanding Shares: 3,338 (As of 8/5/2021)
Shareholders: 1,741
Stock Exchange: OTC
Federal Tax Id: 880292249


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 31, 2024